PRPH2 mutation update: In silico assessment of 245 reported and 7 novel variants in patients with retinal disease

Manon H.C.A. Peeters, Mubeen Khan, Anoek A.M.B. Rooijakkers, Timo Mulders, Lonneke Haer-Wigman, Camiel J.F. Boon, Caroline C.W. Klaver, L. Ingeborgh van den Born, Carel B. Hoyng, Frans P.M. Cremers, Anneke I. den Hollander, Claire Marie Dhaenens, Rob W.J. Collin*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

12 Citations (Scopus)
77 Downloads (Pure)

Abstract

Mutations in PRPH2, encoding peripherin-2, are associated with the development of a wide variety of inherited retinal diseases (IRDs). To determine the causality of the many PRPH2 variants that have been discovered over the last decades, we surveyed all published PRPH2 variants up to July 2020, describing 720 index patients that in total carried 245 unique variants. In addition, we identified seven novel PRPH2 variants in eight additional index patients. The pathogenicity of all variants was determined using the ACMG guidelines. With this, 107 variants were classified as pathogenic, 92 as likely pathogenic, one as benign, and two as likely benign. The remaining 50 variants were classified as variants of uncertain significance. Interestingly, of the total 252 PRPH2 variants, more than half (n = 137) were missense variants. All variants were uploaded into the Leiden Open source Variation and ClinVar databases. Our study underscores the need for experimental assays for variants of unknown significance to improve pathogenicity classification, which would allow us to better understand genotype-phenotype correlations, and in the long-term, hopefully also support the development of therapeutic strategies for patients with PRPH2-associated IRD.

Original languageEnglish
Pages (from-to)1521-1547
Number of pages27
JournalHuman Mutation
Volume42
Issue number12
Early online date19 Aug 2021
DOIs
Publication statusPublished - Dec 2021

Bibliographical note

Funding Information:
We gratefully acknowledge Stéphanie S. Cornelis for the assistance with the statistical analysis and LOVD submission, as well as Bjorn Bakker for technical assistance. Members of the study group (Drs. C. Ayuso; S. Banfi; T. Barakat; N. Bax; T. Ben‐Yosef, M. Breukink; J. de Hoog; J. de Roach; A. Delbecq; J. Ferraz Sallum; K. Fujinami; M. Gorin; W. Hartstra; Y. Hettinga; S. Ijzer; J. Keunen, A. Kievit; T. Kleefstra; T. Lamey; P. Liskova; M. Oldak; J. Ossewaarde ‐ van Norel; M. Phan; O. Podhajcer; P. Rump; M. Sinnema; D. Smailhodzic; C. Stumpel; A. Thiadens; J. van de Ven; R. van Leeuwen; S. Vermeer; J. Verheij and B. Weber) who submitted DNA samples in which variants were identified. This study was supported by an internal RadboudUMC PhD grant provided by the Donders Institute for Brain, Cognition and Behavior, as well as by the Foundation Fighting Blindness USA, grant BR‐GE‐0120‐0775‐LUMC. PRPH2 PRHP2

Funding Information:
We gratefully acknowledge St?phanie S. Cornelis for the assistance with the statistical analysis and LOVD submission, as well as Bjorn Bakker for technical assistance. Members of the PRPH2 study group (Drs. C. Ayuso; S. Banfi; T. Barakat; N. Bax; T. Ben-Yosef, M. Breukink; J. de Hoog; J. de Roach; A. Delbecq; J. Ferraz Sallum; K. Fujinami; M. Gorin; W. Hartstra; Y. Hettinga; S. Ijzer; J. Keunen, A. Kievit; T. Kleefstra; T. Lamey; P. Liskova; M. Oldak; J. Ossewaarde - van Norel; M. Phan; O. Podhajcer; P. Rump; M. Sinnema; D. Smailhodzic; C. Stumpel; A. Thiadens; J. van de Ven; R. van Leeuwen; S. Vermeer; J. Verheij and B. Weber) who submitted DNA samples in which PRHP2 variants were identified. This study was supported by an internal RadboudUMC PhD grant provided by the Donders Institute for Brain, Cognition and Behavior, as well as by the Foundation Fighting Blindness USA, grant BR-GE-0120-0775-LUMC.

Publisher Copyright:
© 2021 The Authors. Human Mutation published Wiley Periodicals LLC

Fingerprint

Dive into the research topics of 'PRPH2 mutation update: In silico assessment of 245 reported and 7 novel variants in patients with retinal disease'. Together they form a unique fingerprint.

Cite this